Metagenomi Therapeutics, Inc. (MGX) Form 10-Q Quarterly Reports
Metagenomi Therapeutics, Inc. (MGX) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: MGX
CIK: 1785279
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
PricewaterhouseCoopers LLP
Auditor SinceSince 12/31/2022 12:00:00 AM
Lead Engagement PartnerGreg Vlahos
Audit LocationSan Jose, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-09-22 | 2026-09-21 | 8-K | 0001193125-26-397037 | View SEC Doc Filr Page |
| 4 | 2026-09-11 | 2026-09-09 | 4 | 0001193125-26-389550 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-09-10 | — | SCHEDULE 13G Filing | 0001193125-26-387853 | View SEC Doc Filr Page |
| 4 | 2026-09-10 | 2026-09-08 | 4 | 0001193125-26-387816 | View SEC Doc Filr Page |
| 4 | 2026-09-10 | 2026-09-08 | 4 | 0001193125-26-387798 | View SEC Doc Filr Page |
| 4 | 2026-09-10 | 2026-09-08 | 4 | 0001193125-26-387786 | View SEC Doc Filr Page |
| 10-Q | 2026-08-10 | 2026-06-30 | 10-Q | 0001193125-26-342400 | View SEC Doc Filr Page |
| 8-K | 2026-08-10 | 2026-08-10 | 8-K | 0001193125-26-342388 | View SEC Doc Filr Page |
| 4 | 2026-06-11 | 2026-06-09 | 4 | 0001193125-26-267272 | View SEC Doc Filr Page |
| 4 | 2026-06-11 | 2026-06-09 | 4 | 0001193125-26-267255 | View SEC Doc Filr Page |
| 4 | 2026-06-11 | 2026-06-09 | 4 | 0001193125-26-267189 | View SEC Doc Filr Page |
| 4 | 2026-06-11 | 2026-06-09 | 4 | 0001193125-26-267170 | View SEC Doc Filr Page |
| 4 | 2026-06-10 | 2026-06-05 | 4 | 0001193125-26-265335 | View SEC Doc Filr Page |
| 4 | 2026-06-10 | 2026-06-05 | 4 | 0001193125-26-265332 | View SEC Doc Filr Page |
| 4 | 2026-06-10 | 2026-06-05 | 4 | 0001193125-26-265326 | View SEC Doc Filr Page |
| 8-K | 2026-06-10 | 2026-06-09 | 8-K | 0001193125-26-264392 | View SEC Doc Filr Page |
| 10-Q | 2026-05-11 | 2026-03-31 | 10-Q | 0001193125-26-216774 | View SEC Doc Filr Page |
| 8-K | 2026-05-11 | 2026-05-11 | 8-K | 0001193125-26-216763 | View SEC Doc Filr Page |
| ARS | 2026-04-27 | 2025-12-31 | ARS | 0001193125-26-182345 | View SEC Doc Filr Page |
| DEFA14A | 2026-04-27 | — | DEFA14A | 0001193125-26-182339 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-27 | 2026-04-21 | DEF 14A | 0001193125-26-182325 | View SEC Doc Filr Page |
| 4 | 2026-04-03 | 2026-04-01 | 4 | 0001193125-26-141946 | View SEC Doc Filr Page |
| 4 | 2026-04-03 | 2026-04-01 | 4 | 0001193125-26-141914 | View SEC Doc Filr Page |
| 4 | 2026-04-03 | 2026-04-01 | 4 | 0001193125-26-141867 | View SEC Doc Filr Page |
| 4 | 2026-03-09 | 2026-03-05 | 4 | 0001193125-26-098824 | View SEC Doc Filr Page |